Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Aveo Pharmaceuticals (NQ: AVEO )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Jan 19, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aveo Pharmaceuticals

CORRECTION – AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee
From AVEO Pharmaceuticals, Inc.
Via GlobeNewswire
AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee
From AVEO Pharmaceuticals, Inc.
Via GlobeNewswire
AVEO Oncology Announces Publication of Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial in The Oncologist
From AVEO Pharmaceuticals, Inc.
Via GlobeNewswire
AVEO Oncology Enrolls First Patient in Pivotal FIERCE-HN Clinical Trial to Evaluate Ficlatuzumab in Combination with ERBITUX® (cetuximab) in Patients with HPV-negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
From AVEO Pharmaceuticals, Inc.
Via GlobeNewswire
LG Chem Completes Acquisition of AVEO Oncology
AVEO to Become the U.S. Foundation for LG Chem Life Sciences’ Oncology Division 
From AVEO Pharmaceuticals, Inc.
Via GlobeNewswire
AVEO Oncology Stockholders Approve Acquisition by LG Chem
From AVEO Pharmaceuticals, Inc.
Via GlobeNewswire
Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel. 
Via MarketBeat
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) Altra Industrial Motion Corp. (Nasdaq - AIMC), UserTesting, Inc. (NYSE - USER), AVEO Pharmaceuticals, Inc. (Nasdaq - AVEO), Limestone Bancorp, Inc. (Nasdaq - LMST)
From Brodsky & Smith LLC
Via GlobeNewswire
AVEO ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AVEO Oncology - AVEO
From Kahn Swick & Foti, LLC
Via Business Wire
AVEO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of AVEO Pharmaceuticals, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
LG Chem to Acquire AVEO Oncology for $15.00 Per Share in Cash
From AVEO Pharmaceuticals, Inc.
Via GlobeNewswire
NiKang Therapeutics and AVEO Oncology Announce a Clinical Trial Collaboration and Supply Agreement to Evaluate the Combination of NKT2152, a HIF2α Inhibitor, and FOTIVDA® (tivozanib) for the Treatment of Advanced Clear Cell Renal Cell Carcinoma
From NiKang Therapeutics Inc.
Via Business Wire
AVEO Oncology Announces Appointment of Jeb Ledell as Chief Operating Officer
From AVEO Oncology
Via Business Wire
AVEO Oncology Announces Participation at Two Upcoming Virtual Investor Conferences
From AVEO Oncology
Via Business Wire
AVEO Oncology Reports Third Quarter 2021 Financial Results and Provides Business Update
From AVEO Oncology
Via Business Wire
AVEO Oncology to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 8, 2021
From AVEO Oncology
Via Business Wire
AVEO Oncology Announces Ficlatuzumab Granted Fast Track Designation by the U.S. FDA for the Treatment of Relapsed or Recurrent Head and Neck Squamous Cell Carcinoma
From AVEO Oncology
Via Business Wire
AVEO Oncology Announces Participation at Two Upcoming Virtual Investor Conferences
From AVEO Oncology
Via Business Wire
AVEO Oncology Reports Second Quarter 2021 Financial Results and Provides Business Update
From AVEO Oncology
Via Business Wire
AVEO Oncology to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5, 2021
From AVEO Oncology
Via Business Wire
AVEO Oncology to Host Key Opinion Leader Webinar on FOTIVDA® (tivozanib) for Relapsed or Refractory Renal Cell Carcinoma
From AVEO Oncology
Via Business Wire
AVEO Oncology to Host Key Opinion Leader Webinar on Ficlatuzumab in Head and Neck Squamous Cell Carcinoma
From AVEO Oncology
Via Business Wire
AVEO Oncology to Present at the Jefferies 2021 Virtual Healthcare Conference
From AVEO Oncology
Via Business Wire
AVEO Oncology Announces Presentation of Long-Term Efficacy Follow Up, Additional Tolerability Data from the Phase 3 TIVO-3 Study of FOTIVDA® (tivozanib) in Relapsed or Refractory Renal Cell Carcinoma
From AVEO Oncology
Via Business Wire
AVEO Oncology Announces Positive Results from Randomized Phase 2 Study of Ficlatuzumab in Combination with Cetuximab in Pan-Refractory, Metastatic HNSCC
From AVEO Oncology
Via Business Wire
AVEO Oncology Reports First Quarter 2021 Financial Results and Provides Business Update
From AVEO Oncology
Via Business Wire
AVEO Oncology to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 10, 2021
From AVEO Pharmaceuticals, Inc.
Via Business Wire
AVEO Announces Appointment of Kevin Cullen, M.D., to Its Board of Directors
From AVEO Oncology
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.